Evidence shows that targeting the IL-1 pathway in new-onset sJIA with predominant systemic features leads to better outcomes, enabling lower glucocorticoid doses, shorter treatment durations and improved long-term outcomes. Here, IL1B is linked to systemic-onset juvenile idiopathic arthritis.